Paolo Tarantino reflects on the results from DESTINY-CRC02 published in the Lancet Oncology
Paolo Tarantino shared on X:
“Results from DESTINY-CRC02 published in the Lancet Oncology. Among patients with pretreated, HER2+ mCRC, the lower dose of T-DXd (5.4 mg/kg) led to higher ORR and longer PFS than the higher dose (6.4 mg/kg), with nearly half the rate of ILD. Less can be more.”
Source: Paolo Tarantino/X
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
Autors: Kanwal Raghav, Salvatore Siena, Atsuo Takashima, Takeshi Kato, Marc Van den Eynde, Filippo Pietrantonio, Yoshito Komatsu, Hisato Kawakami, Marc Peeters, Thierry Andre, Sara Lonardi, Kensei Yamaguchi, Jeanne Tie, Cristina Gravalos Castro, Hung-Chih Hsu, John H Strickler, Tae-You Kim, Yongjun Cha, Daniel Barrios, Qi Yan, Takahiro Kamio, Kojiro Kobayashi, Aislyn Boran, Makito Koga, John D Allard, Takayuki Yoshino
“Similar to DESTINY-CRC01, most responses were seen in HER2 IHC 3+ tumors. HER2 expression does matter, for T-DXd efficacy.”
Source: Paolo Tarantino/X
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023